ALBIREO PHARMA WKN: A2DF99 ISIN: US01345P1066 Kürzel: BDQM Forum: Aktien Thema: Hauptdiskussion

👀

Albireo gibt Vereinbarung zur Monetarisierung von Lizenzgebühren in Höhe von 115 Millionen US-Dollar mit Sagard bekannt

🤩

Reports Positive Topline Data from Phase 3 Trial of Bylvay (odevixibat) in Alagille Syndrome. Highly statistically significant improvement in pruritus primary endpoint (p=0.002) Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)

Albireo Pharma präsentiert Daten aus den Phase-3-Studien PEDFIC 1 und PEDFIC 2

Albireo Pharma, Inc. (NASDAQ:ALBO) Expected to Post Quarterly Sales of $12.30 Million Posted on Wednesday, February 2nd, 2022 by MarketBeat Brokerages forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will post $12.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Albireo Pharma's earnings, with the highest sales estimate coming in at $23.12 million and the lowest estimate coming in at $5.01 million. Albireo Pharma reported sales of $2.72 million in the same quarter last year, which would suggest a positive year over year growth rate of 352.2%. The company is scheduled to report its next earnings results on Thursday, February 24th. According to Zacks, analysts expect that Albireo Pharma will report full-year sales of $18.34 million for the current financial year, with estimates ranging from $12.00 million to $31.18 million. For the next fiscal year, analysts forecast that the business will report sales of $53.22 million, with estimates ranging from $42.48 million to $58.67 million. Zacks Investment Research's sales calculations are an average based on a survey of research firms that cover Albireo Pharma. Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $3.28. The business had revenue of $3.66 million during the quarter, compared to the consensus estimate of $22.33 million. Albireo Pharma had a negative net margin of 444.28% and a negative return on equity of 82.99%. During the same quarter in the prior year, the firm posted ($1.96) earnings per share.

Ja geringer Freefloat und hoher Anteil an institutionellen Anleger.

ich versteh das nicht. ich verfolge die aktie seit einem jahr und lese in den foren. alle haben teils 3 oder sogar mehr jahre hier auf diesen einen moment gewartet. nun ist er schon seit langem da und die aktie reagiert mit abverkauf. lässt sich das überhaupt erklären?

Man lernt nicht aus…

Geringes Volumen, geringer Freefloat

Was ist denn da los mit dem Kurs? Sollte der nicht steigen?

Zum heulen ist das gerade. Wahnsinn.

Juhu

Approval!!

Da wird ganz schön der Kurs manipuliert